PSILX vs. FMED

Last updated Jun 16, 2026

PSILX (T. Rowe Price Spectrum International Equity Fund) and FMED (Fidelity Disruptive Medicine ETF) are both funds - PSILX is a Foreign Large Cap Equities fund managed by T. Rowe Price, while FMED is a Health & Biotech Equities fund actively managed by Fidelity. Over the past 3 years, PSILX returned 16.34%/yr vs 0.73%/yr for FMED. A 0.56 correlation means they provide meaningful diversification when combined. PSILX charges 0.89%/yr vs 0.50%/yr for FMED.

Performance

PSILX vs. FMED - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in T. Rowe Price Spectrum International Equity Fund (PSILX) and Fidelity Disruptive Medicine ETF (FMED). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PSILX achieves a 12.26% return, which is significantly higher than FMED's -4.75% return.

PSILX

• 1D: 0.46%
• 1M: 3.76%
• YTD: 12.26%
• 6M: 14.02%
• 1Y: 27.05%
• 3Y*: 16.34%
• 5Y*: 6.27%
• 10Y*: 8.88%

FMED

• 1D: 0.90%
• 1M: 7.10%
• YTD: -4.75%
• 6M: -6.17%
• 1Y: 8.53%
• 3Y*: 0.73%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PSILX vs. FMED - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
PSILX T. Rowe Price Spectrum International Equity Fund	12.26%	30.30%	4.28%	4.70%
FMED Fidelity Disruptive Medicine ETF	-4.75%	9.69%	2.29%	-3.59%

Correlation

The correlation between PSILX and FMED is 0.55, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.55
Correlation (3Y) Calculated over the trailing 3-year period	0.56
Correlation (All Time) Calculated using the full available price history since Jun 12, 2023	0.56

The correlation between PSILX and FMED has been stable across timeframes, ranging from 0.55 to 0.56 - a consistent structural relationship.

Return for Risk

PSILX vs. FMED — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PSILX

PSILX Risk / Return Rank: 40
PSILX Sharpe Ratio Rank: 40
PSILX Sortino Ratio Rank: 39
PSILX Omega Ratio Rank: 43
PSILX Calmar Ratio Rank: 37
PSILX Martin Ratio Rank: 40

FMED

FMED Risk / Return Rank: 15
FMED Sharpe Ratio Rank: 16
FMED Sortino Ratio Rank: 16
FMED Omega Ratio Rank: 15
FMED Calmar Ratio Rank: 14
FMED Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PSILX vs. FMED - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for T. Rowe Price Spectrum International Equity Fund (PSILX) and Fidelity Disruptive Medicine ETF (FMED). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PSILX	FMED	Difference
Sharpe ratio: Return per unit of total volatility	1.59	0.44	+1.15
Sortino ratio: Return per unit of downside risk	2.25	0.79	+1.46
Omega ratio: Gain probability vs. loss probability	1.30	1.09	+0.22
Calmar ratio: Return relative to maximum drawdown	2.04	0.47	+1.57
Martin ratio: Return relative to average drawdown	7.72	1.03	+6.68

PSILX vs. FMED - Sharpe Ratio Comparison

The current PSILX Sharpe Ratio is 1.59, which is higher than the FMED Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of PSILX and FMED, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PSILX vs. FMED - Drawdown Comparison

The maximum PSILX drawdown since its inception was -61.38%, which is greater than FMED's maximum drawdown of -21.84%. Use the drawdown chart below to compare losses from any high point for PSILX and FMED.

Drawdown Indicators

	PSILX	FMED	Difference
Max Drawdown Largest peak-to-trough decline	-61.38%	-21.84%	-39.54%
Max Drawdown (1Y) Largest decline over 1 year	-12.72%	-18.33%	+5.61%
Max Drawdown (3Y) Largest decline over 3 years	-13.70%	-21.84%	+8.14%
Max Drawdown (5Y) Largest decline over 5 years	-33.13%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-33.33%	—	—
Current Drawdown Current decline from peak	-1.66%	-10.64%	+8.98%
Average Drawdown Average peak-to-trough decline	-14.05%	-7.09%	-6.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.32%	8.27%	-4.95%

Volatility

PSILX vs. FMED - Volatility Comparison

The current volatility for T. Rowe Price Spectrum International Equity Fund (PSILX) is 6.70%, while Fidelity Disruptive Medicine ETF (FMED) has a volatility of 7.50%. This indicates that PSILX experiences smaller price fluctuations and is considered to be less risky than FMED based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PSILX	FMED	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.70%	7.50%	-0.80%
Volatility (6M) Calculated over the trailing 6-month period	14.03%	15.01%	-0.98%
Volatility (1Y) Calculated over the trailing 1-year period	16.33%	19.37%	-3.04%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	15.94%	18.57%	-2.63%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	16.28%	18.57%	-2.29%

PSILX vs. FMED - Expense Ratio Comparison

PSILX has a 0.89% expense ratio, which is higher than FMED's 0.50% expense ratio.

Dividends

PSILX vs. FMED - Dividend Comparison

PSILX's dividend yield for the trailing twelve months is around 4.83%, while FMED has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
FMED Fidelity Disruptive Medicine ETF	0.00%	0.00%	0.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PSILX T. Rowe Price Spectrum International Equity Fund	4.83%	5.42%	2.04%	1.88%	6.67%	3.49%	0.88%	3.49%	6.69%	0.58%	0.17%	0.08%

Frequently Asked Questions

Can I hold both PSILX and FMED in my portfolio?

PSILX and FMED have a correlation of 0.55, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PSILX or FMED?

FMED has higher volatility (7.50%) compared to PSILX (6.70%). In terms of maximum drawdown, PSILX dropped -61.38% vs FMED's -21.84%.

Which has better risk-adjusted returns?

PSILX currently has the higher Sharpe Ratio (1.59 vs 0.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.